All the latest news on the marijuana space delivered directly to your inbox.
TheSeedInvestor
Read our Investor Dashboard on OTC:ABCCF TSX.v ABCN
There will be a sudden wave of "Marijuana Millionaires" in 2017 - will you be one?

 
13x13x1 READ MORE
Read the Investors Guide To Newly Emerging Marijuana Markets 
LEARN MORE
600x300
Choom™ (CSE: CHOO | OTC: CHOOF) to Acquire 2nd Late Stage ACMPR Applicant
Choom™ (CSE: CHOO; OTCQB: CHOOF) is pleased to announce it has signed a Letter of Intent to acquire its second, advanced-stage cannabis production licence applicant ("Target") under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR).
13x13x1 READ MORE
600x300
ABcann Granted Australian Import License
ABCANN GLOBAL CORPORATION (TSXV: ABCN) is pleased to announce that its wholly-owned subsidiary, ABcann Australia Pty Ltd., has received an import license from the Federal Office of Drug Control in Australia.
13x13x1 READ MORE
600x300
DOJA Cannabis and Tokyo Smoke Announce Signing of Definitive Business Combination Agreement
Further to their joint news release dated December 21, 2017, DOJA Cannabis Company Limited (CSE: DOJA) and TS Brandco Holdings Inc. ("Tokyo Smoke") are pleased to announce the signing of a definitive business combination agreement effective as of January 17, 2018, whereby DOJA will acquire all of the issued and outstanding securities of Tokyo Smoke by way of a three-cornered amalgamation.
13x13x1 READ MORE
600x300
CanniMed Therapeutics Postpones Special Shareholders’ Meeting
CanniMed has determined to postpone the Meeting to allow discussions regarding a possible transaction with Aurora Cannabis Inc. as permitted under the terms of the Arrangement Agreement between CanniMed and Newstike
13x13x1 READ MORE
Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
 
32x32x1   32x32x2   32x32x3
TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260
info@theseedinvestor.com
 
©2018, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.